Home › Research › Drug development
Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial
Matthew Philip Gilbert, Stephen Charles Bain, Edward Franek, Esteban Jódar-Gimeno, Michael Albrecht Nauck, Richard E. Pratley, Rosangela Roginski Rea, José Francisco Kerr Saraiva et al.. Annals of Internal Medicine, 2018-12-03
Topic: Drug trials: efficacy and safety
Plain-language summary
Buse, MD PhDDiabetes Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina (J.B.B.), and the LEADER Publication Committee on behalf of the LEADER Trial Investigators*Author, Article, and Disclosure Informationhttps://doi.org/10.7326/M18-1569 SectionsSupplemental MaterialAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Comorbidities and complications associated with type 2 diabetes mellitus (T2DM) increase with age, making treatment of elderly persons with this condition challenging. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byNewer Glucose-Lowering Therapies in Older Adults with Type 2 DiabetesComparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient CharacteristicsHypoglycaemic therapy in frail older people with type 2 diabetes mellitus—a choice determined by metabolic phenotypeLe risque de dénutrition chez le sujet âgé diabétique : une limite à l'utilisation des « nouvelles » classes thérapeutiques ?Cardiovascular disease in the elderly: proceedings of the European Society of Cardiology—Cardiovascular Round TableCardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonistsCardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanismsOptimal Type 2 Diabetes Mellitus Management and Active AgeingLow glycaemic state increases risk of frailty and functional decline in older people with type 2 diabetes mellitus – Evidence from a systematic reviewDipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysisType 2 diabetes mellitus in older adults: clinical considerations and managementApproach to Obesity in the Older PopulationNewer anti-diabetic therapies with low hypoglycemic risk-potential advantages for frail older peopleDirection for Basal Insulin Therapy by Once Daily Injection in the Clinical PracticeEfficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trialGLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysisCardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with t
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Gilbert, M. P., Bain, S. C., Franek, E., Jódar-Gimeno, E., Nauck, M. A., Pratley, R. E., et al. (2018). Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial. Annals of Internal Medicine. https://doi.org/10.7326/m18-1569
Vancouver
Gilbert MP, Bain SC, Franek E, Jódar-Gimeno E, Nauck MA, Pratley RE, et al. Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial. Annals of Internal Medicine. 2018. doi:10.7326/m18-1569. PMID: 30508430.
BibTeX
@article{gilbert2018-30508430,
author = {Gilbert, Matthew Philip and Bain, Stephen Charles and Franek, Edward and Jódar-Gimeno, Esteban and Nauck, Michael Albrecht and Pratley, Richard E. and Rea, Rosangela Roginski and Saraiva, José Francisco Kerr and others},
title = {{Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial}},
journal = {Annals of Internal Medicine},
year = {2018},
doi = {10.7326/m18-1569},
pmid = {30508430},
url = {https://doi.org/10.7326/m18-1569}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Buse, MD PhDDiabetes Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina (J.B.B.), and the LEADER Publication Committee on behalf of the LEADER Trial Investigators*Author, Article, and Disclosure Informationhttps://doi.org/10.7326/M18-1569 SectionsSupplemental MaterialAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Comorbidities and complications associated with type 2 diabetes mellitus (T2DM) increase with age, making treatment of elderly persons with this condition challenging.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designrandomized controlled trial
- Evidence strengthHigh
How this study scored 69/100
Published in a leading specialty journal, and it is a randomized controlled trial. Scored zero for sample size, effect reported and studied in people because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 40 of the 58 points we could judge it on, which is 69 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Annals of Internal Medicine) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 11 / 12 | A randomized controlled trial |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2018 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 30508430) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 40 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 40 of the 58 points we could judge it on is 69 out of 100. |
| Total | 69 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Drug development from nearby years
Also in Drug development
124 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.